Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics
CRDF Price/Volume Stats
| Current price | $1.60 | 52-week high | $2.79 |
| Prev. close | $1.62 | 52-week low | $1.20 |
| Day low | $1.58 | Volume | 22,707,200 |
| Day high | $2.01 | Avg. volume | 473,932 |
| 50-day MA | $1.75 | Dividend yield | N/A |
| 200-day MA | $1.65 | Market Cap | 71.48M |
CRDF Stock Price Chart Interactive Chart >
CRDF POWR Grades
- CRDF scores best on the Sentiment dimension, with a Sentiment rank ahead of 89.71% of US stocks.
- CRDF's strongest trending metric is Growth; it's been moving down over the last 177 days.
- CRDF's current lowest rank is in the Momentum metric (where it is better than 5.22% of US stocks).
CRDF Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CRDF is 0 -- better than only 9.04% of US stocks.
- CRDF's price/sales ratio is 174.59; that's higher than the P/S ratio of 98.37% of US stocks.
- CRDF's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 9.04% of US stocks.
- If you're looking for stocks that are quantitatively similar to CARDIFF ONCOLOGY INC, a group of peers worth examining would be LYRA, CRIS, GWH, SPCE, and EDIT.
- CRDF's SEC filings can be seen here. And to visit CARDIFF ONCOLOGY INC's official web site, go to www.cardiffoncology.com.
CRDF Valuation Summary
- CRDF's price/sales ratio is 174.5; this is 9084.21% higher than that of the median Healthcare stock.
- CRDF's price/sales ratio has moved down 2112.3 over the prior 198 months.
Below are key valuation metrics over time for CRDF.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CRDF | 2023-09-22 | 174.5 | 0.8 | -1.8 | -1.4 |
| CRDF | 2023-09-21 | 177.9 | 0.8 | -1.8 | -1.4 |
| CRDF | 2023-09-20 | 176.7 | 0.8 | -1.8 | -1.4 |
| CRDF | 2023-09-19 | 176.7 | 0.8 | -1.8 | -1.4 |
| CRDF | 2023-09-18 | 183.3 | 0.9 | -1.9 | -1.5 |
| CRDF | 2023-09-15 | 187.6 | 0.9 | -1.9 | -1.5 |
CRDF Growth Metrics
- The 4 year price growth rate now stands at -98.06%.
- The 3 year cash and equivalents growth rate now stands at 76.98%.
- Its 5 year revenue growth rate is now at -1.51%.
The table below shows CRDF's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.391 | -31.82 | -39.473 |
| 2022-06-30 | 0.384 | -29.799 | -37.815 |
| 2022-03-31 | 0.361 | -27.405 | -34.129 |
| 2021-12-31 | 0.359 | -23.04 | -28.315 |
| 2021-09-30 | 0.345255 | -20.77394 | -25.47011 |
| 2021-06-30 | 0.395656 | -18.83417 | -23.0537 |
CRDF's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CRDF has a Quality Grade of D, ranking ahead of 16.71% of graded US stocks.
- CRDF's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
- OTIC, AVDL, and CORT are the stocks whose asset turnover ratios are most correlated with CRDF.
The table below shows CRDF's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.004 | 1 | -0.388 |
| 2021-03-31 | 0.004 | 1 | -0.758 |
| 2020-12-31 | 0.007 | 1 | 17.949 |
| 2020-09-30 | 0.014 | 1 | 22.880 |
| 2020-06-30 | 0.015 | 1 | 50.452 |
| 2020-03-31 | 0.028 | 1 | -56.954 |
CRDF Price Target
For more insight on analysts targets of CRDF, see our CRDF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.33 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Cardiff Oncology, Inc. (CRDF) Company Bio
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CRDF News From Around the Web
Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.
Cardiff Oncology to Present at Upcoming Investor Conferences in SeptemberCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will present at the Baird Global Healthcare Conference on September 12, 2023 and the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. |
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business UpdateCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. |
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer RelationshipCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced plans to advance the company's lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct its new CRDF-004 trial with study execution support from Pfizer Ignite, a new end-to-end service for biotech companies. |
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that on July 24, 2023, non-qualified stock option awards to purchase an aggregate of 50,016 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance wi |
Cardiff Oncology to Present at the Jefferies Healthcare ConferenceCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 7-9, 2023. |
CRDF Price Returns
| 1-mo | -14.44% |
| 3-mo | 8.84% |
| 6-mo | -3.03% |
| 1-year | -3.61% |
| 3-year | -86.86% |
| 5-year | -67.28% |
| YTD | 14.29% |
| 2022 | -76.71% |
| 2021 | -66.59% |
| 2020 | 1,350.81% |
| 2019 | -60.63% |
| 2018 | -85.80% |
Loading social stream, please wait...